Vision Loss in Older Adults

ALLEN L. PELLETIER, MD; LEDY ROJAS-ROLDAN, MD; and JANIS COFFIN, DO
Medical College of Georgia at Augusta University, Augusta, Georgia

Vision loss affects 37 million Americans older than 50 years and one in four who are older than 80 years. The U.S. Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in adults older than 65 years. However, family physicians play a critical role in identifying persons who are at risk of vision loss, counseling patients, and referring patients for disease-specific treatment. The conditions that cause most cases of vision loss in older patients are age-related macular degeneration, glaucoma, ocular complications of diabetes mellitus, and age-related cataracts. Vitamin supplements can delay the progression of age-related macular degeneration. Intravitreal injection of a vascular endothelial growth factor inhibitor can preserve vision in the neovascular form of macular degeneration. Medicated eye drops reduce intraocular pressure and can delay the progression of vision loss in patients with glaucoma, but adherence to treatment is poor. Laser trabeculoplasty also lowers intraocular pressure and preserves vision in patients with primary open-angle glaucoma, but long-term studies are needed to identify who is most likely to benefit from surgery. Tight glycemic control in adults with diabetes slows the progression of diabetic retinopathy, but must be balanced against the risks of hypoglycemia and death in older adults. Fenofibrate also slows progression of diabetic retinopathy. Panretinal photocoagulation is the mainstay of treatment for diabetic retinopathy, whereas vascular endothelial growth factor inhibitors slow vision loss resulting from diabetic macular edema. Preoperative testing before cataract surgery does not improve outcomes and is not recommended. (Am Fam Physician. 2016;94(3):219-226. Copyright © 2016 American Academy of Family Physicians.)

Vison loss is common and consequential among older adults. Family physicians play a critical role in identifying persons who are at risk of vision loss, counseling patients, and referring patients for disease-specific treatment.

The prevalence of all-cause vision loss increases with age, affecting 37 million Americans older than 50 years and 25% of those older than 80 years (Figure 1). Approximately 7% of adults 65 years and older report disability related to impaired vision. A 2013 review estimated that the indirect and direct costs of treating adults with visual impairment is $54 billion annually. Vision loss in older adults is associated with increased fall risk, loss of independence, depression, and increased all-cause mortality. Most cases of vision loss in older adults are due to defined diseases for which there are effective strategies to prevent or delay vision loss and blindness.

Definitions and Legal Issues

Low vision is defined as central visual acuity of 20/70 or worse in the better-seeing eye with best correction or a total visual field loss of 140 degrees. Legal blindness is defined as central visual acuity of 20/200 or worse in the better-seeing eye with best correction or a visual field of 20 degrees or less. Persons with legal blindness may still have adequate vision to maintain activities of daily living and function independently.

A determination of legal blindness may qualify affected persons for Social Security or other disability benefits. A clinical guide to vision assessment in older drivers, including state-specific requirements and counseling recommendations, is available through the American Geriatrics Society.
Screening

The U.S. Preventive Services Task Force (USPSTF) concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults. The USPSTF found no well-designed studies demonstrating conclusive benefits of universal eye screening in older adults. Based on expert consensus, the American Academy of Ophthalmology recommends comprehensive eye examinations every one to two years for all adults 65 years and older. A comprehensive eye examination includes a visual acuity test, pharmacologic dilation of the pupil, tonometry, and visual field testing.

Major Causes

The four major causes of severe vision loss and blindness in older adults are age-related macular degeneration (AMD), ocular complications of diabetes mellitus, glaucoma, and age-related cataracts. Table 1 summarizes these etiologies. Refractive error is an important correctable cause of visual impairment, but it is not discussed in this review.

Age-Related Macular Degeneration

Two retinal pigment abnormalities, retinal geographic atrophy and drusen (yellow deposits under the retina made up of lipids), predominate in dry (nonexudative) AMD (Figure 2). Dry AMD can progress to the more severe wet (exudative or neovascular) type (Figure 3), which is characterized by neovascularization and hemorrhage in the macula. In a long-term follow-up study of patients with AMD, 70.9% of participants with bilateral medium drusen at enrollment progressed to large drusen, and 13.8% progressed to advanced AMD over 10 years.

The Amsler grid can be used to identify defects in central vision and monitor visual changes in patients with established AMD. Patients are asked to fix their gaze on the black dot in the center and report whether any grid lines appear to be missing or distorted, indicating an abnormality (Figure 4). New or worsening abnormalities warrant referral to an ophthalmologist.

TREATMENT

Vitamin Supplements. The Age-Related Eye Disease Study (AREDS) is a randomized controlled trial that tested the effectiveness of an antioxidant vitamin supplement in 3,640 patients with AMD who were 55 to 80 years of age. Patients in the active treatment arm who had moderate to severe AMD at enrollment had a lower risk of disease progression compared with those receiving placebo over 6.3 years of follow-up (26.7% vs. 35.7%);

**Table 1.** Age-adjusted prevalence of all-cause visual impairment in adults.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-49</td>
<td>5</td>
</tr>
<tr>
<td>50-54</td>
<td>15</td>
</tr>
<tr>
<td>55-59</td>
<td>20</td>
</tr>
<tr>
<td>60-64</td>
<td>25</td>
</tr>
<tr>
<td>65-69</td>
<td>30</td>
</tr>
<tr>
<td>70-74</td>
<td>30</td>
</tr>
<tr>
<td>75-79</td>
<td>25</td>
</tr>
<tr>
<td>80+</td>
<td>10</td>
</tr>
</tbody>
</table>

number needed to treat = 11). Supplements do not prevent the development of AMD. Because beta-carotene supplements were subsequently associated with increased lung cancer rates in patients who smoke tobacco, a second trial (AREDS2) randomized participants to a revised supplement containing lutein plus zeaxanthin, omega-3 fatty acids, or both. Removal of beta-carotene had no effect on AMD progression. Omega-3 fatty acid supplementation offered no benefit beyond the original AREDS formulation. Lutein plus zeaxanthin appeared to offer no additional benefit in the general study population. Secondary analysis of the subgroup with large drusen at enrollment, however, suggested that lutein plus zeaxanthin may provide modest additional benefit in preventing progression to advanced AMD (hazard ratio = 0.76; 95% confidence interval, 0.61 to 0.96) and development of neovascular AMD (hazard ratio = 0.65; 95% confidence interval, 0.49 to 0.85). Lutein plus zeaxanthin also appears to be safe, with no increased risk of lung cancer.

### Table 1. Major Causes of Vision Loss in Older Adults

<table>
<thead>
<tr>
<th>Disease</th>
<th>Epidemiology</th>
<th>Clinical presentation</th>
<th>Screening recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age-related cataracts</td>
<td>Cases in U.S. adults 40 years and older (2010): 24.4 million Estimated cases by 2050: 50 million By 75 years of age, 50% of whites will have cataracts in one or both eyes; 70% will have them by 80 years of age 53% of blacks and 61% of Hispanics will be affected by 80 years of age The greatest rate increase by 2050 is expected in Hispanics, with an increase from 1.76 million to 9.51 million</td>
<td>Vision loss Glare intolerance and halos, especially at night or while driving</td>
<td>No specific screening recommendations; treatment is not needed until patients experience bothersome visual symptoms</td>
</tr>
<tr>
<td>Age-related macular degeneration</td>
<td>Cases in U.S. adults 50 years and older (2010): 2.44 million Estimated cases by 2050: 5.44 million Affects 2.5% of whites 50 years and older vs. 0.9% of blacks, Hispanics, and persons of other races Risk rises sharply for persons older than 80 years; prevalence among this age group in the United States is 11% overall and 13.8% among whites The greatest rate increase by 2050 will likely be among Hispanics, with a nearly sixfold rise</td>
<td>Vision loss Difficulties with dark adaptation Positive Amsler grid test result</td>
<td>Patients with early age-related macular degeneration or a family history of the disease should be encouraged to assess their own vision (i.e., with an Amsler grid) and to see an ophthalmologist for dilated eye examinations (age to begin screening and optimal examination interval are not specified)</td>
</tr>
<tr>
<td>Diabetic eye disease</td>
<td>Cases in U.S. adults (2010): 7.7 million Estimated cases by 2050: 14.6 million Hispanics 50 years and older have the highest rates of diabetic retinopathy, with cases projected to increase from 1.2 million to 5.3 million by 2050</td>
<td>Vision loss Fluctuating vision Presence of floaters Flashes of light (photopsia) Defects in the field of vision</td>
<td>Older adults with diabetes mellitus should be referred to an ophthalmologist at diagnosis for dilated eye examination, and reexamined at least annually; it is reasonable to discontinue these examinations in older adults with no or mild diabetic eye disease and life-limiting conditions (e.g., end-stage renal disease)</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Cases in U.S. adults 40 years and older (2010): 2.7 million Estimated cases by 2050: 6.3 million Blacks 40 years and older are at the highest risk By 69 years of age, 6% of U.S. blacks will have glaucoma; risk increases to 12% after 80 years of age</td>
<td>No symptoms in the early stages Peripheral visual field loss and progressive central vision loss become apparent as the disease advances Once established, vision loss is permanent</td>
<td>Current evidence is insufficient to assess the balance of benefits and harms of screening for primary open-angle glaucoma in adults, according to the U.S. Preventive Services Task Force Screening of high-risk groups (e.g., blacks, Hispanics, persons with a family history of glaucoma) should be considered Complete screening includes measurement of visual acuity, measurement of intraocular pressure, and automated visual field testing</td>
</tr>
</tbody>
</table>

Information from references 15 through 22.
The original AREDS and modified AREDS2 formulations (Table 2) are sold over the counter. Current or former smokers should be counseled to avoid the original AREDS formula containing beta-carotene.

Vascular Endothelial Growth Factor Inhibitors. The use of vascular endothelial growth factor inhibitors by intravitreal injection is a major advancement in the treatment of neovascular AMD. Injections are administered once monthly for four months or until vision stabilizes, then every three months thereafter. The safety and effectiveness of this intervention have not been evaluated past 24 months.

Ranibizumab (Lucentis) and bevacizumab (Avastin) appear to be slightly more effective than pegaptanib (Macugen), with similar adverse effect and safety profiles. Pegaptanib, ranibizumab, and aflibercept (Eylea) are approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular AMD. Bevacizumab has to be compounded for intravitreal injection and is not FDA approved for AMD treatment. The cost of bevacizumab is significantly lower per dose than other, FDA-approved agents (approximately $150 vs. $1,500 to $2,000). Many ophthalmologists favor using the less-expensive bevacizumab instead of ranibizumab, citing comparable safety and effectiveness; however, the manufacturer, which produces both drugs, has not sought FDA approval for bevacizumab.

A contaminated lot of compounded bevacizumab caused 12 cases of severe eye infection in 2011. Excluding this outbreak, which was traced to a single compounding supplier, bevacizumab has a similar safety profile to the other, FDA-approved agents.

Glaucoma

CLASSIFICATION AND DIAGNOSIS

Glaucoma is a heterogeneous group of ophthalmic conditions that cause progressive damage to the optic nerve, leading to visual field loss and irreversible blindness.
Vision Loss in Older Adults

Primary open-angle glaucoma and primary angle-closure glaucoma are the most common forms. Most patients with glaucoma have ocular hypertension (elevated intracocular pressure), but optic nerve damage can also occur with normal intracocular pressure. Diagnosis requires measurement of intracocular pressure in conjunction with evaluation of the optic disc and an automated visual field test.

SCREENING AND PREVENTION

The USPSTF found insufficient evidence to assess the balance of benefits and harms of screening for primary open-angle glaucoma, but recognizes that certain subpopulations (e.g., persons with a family history of glaucoma, blacks, Hispanics) are at higher risk of the disease and may be more likely to benefit from referral for periodic intracocular pressure measurement and automated visual field testing.

TREATMENT

A number of medicated eye drops lower intracocular pressure and can delay the progression of vision loss. Long-term adherence to therapy remains a major problem; continuation rates are typically less than 50% at one year. Simplifying eye drop regimens, providing patient education, coaching on proper eye drop technique, and offering ongoing support to patients may improve adherence. Because adherence to medical therapy for glaucoma is poor, there is interest in surgical approaches to stop progression of glaucoma before vision loss becomes irreversible. Laser trabeculoplasty for primary open-angle glaucoma appears to be safe and effective in lowering intraocular pressure and preserving vision. Long-term studies are needed to identify which patients are most likely to benefit from surgery, the optimal technique, and the effectiveness of repeat procedures.

Diabetic Eye Disease

SCREENING AND MONITORING

Older adults with type 2 diabetes should be referred to an ophthalmologist at diagnosis for dilated eye examination, and reexamined at least annually. It is reasonable to discontinue these examinations in older adults with no or mild diabetic eye disease and life-limiting conditions (e.g., end-stage renal disease).

SLOWING DISEASE PROGRESSION

Glycemic Control. Several large clinical trials have demonstrated that tight glycemic control decreases the risk of progression of diabetic retinopathy. It is unclear how these results apply to the care of older adults with diabetes, who often have multiple comorbidities that complicate diabetes management and are at risk of hypoglycemia and increased all-cause mortality with tight glycemic control. The American Diabetes Association revised consensus guidelines recommend individualized adjustment of A1C goals (target range of 8.5%) in older adults.

Fenofibrate. Two large clinical trials have demonstrated that fenofibrate (Tricor) increases the time to first laser treatment and slows the overall progression of diabetic retinopathy, regardless of its effect on plasma lipid levels.

TREATMENT OF PROGRESSIVE DIABETIC RETINOPATHY

Photocoagulation. Nonproliferative diabetic retinopathy with preserved visual acuity can be monitored without

Table 2. Supplements to Delay Progression of Age-Related Macular Degeneration

<table>
<thead>
<tr>
<th>AREDS supplements</th>
<th>AREDS2 supplements</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 mg vitamin C</td>
<td>500 mg vitamin C</td>
</tr>
<tr>
<td>400 IU vitamin E</td>
<td>400 IU vitamin E</td>
</tr>
<tr>
<td>15 mg beta-carotene*</td>
<td>25 mg zinc</td>
</tr>
<tr>
<td>80 mg zinc as zinc oxide</td>
<td>2 mg copper as cupric oxide</td>
</tr>
<tr>
<td>2 mg copper as cupric oxide</td>
<td>10 mg lutein plus 2 mg zeaxanthin</td>
</tr>
</tbody>
</table>

*—Associated with increased rates of lung cancer in smokers.

Information from reference 32.

Figure 5. Advanced glaucoma. Typical features include enlarged, pale optic disc and increased cup/disc ratio.
active treatment. Widespread neovascularization and hemorrhage indicate progression to proliferative diabetic retinopathy (Figure 6), which requires treatment, typically with panretinal photocoagulation.50

Vascular endothelial growth factor inhibitors. Based on low-quality evidence, a Cochrane review concluded that vascular endothelial growth factor inhibitors have limited effectiveness for proliferative diabetic retinopathy.51 However, they may have a role if standard therapy is ineffective or vitreous hemorrhage occurs.52

TREATMENT OF DIABETIC MACULAR EDEMA

Diabetic macular edema causes rapid vision deterioration and can quickly lead to blindness. Aflibercept, bevacizumab, and ranibizumab have been studied for diabetic macular edema with comparable effectiveness, adverse effects, and safety profiles.53,54 Aflibercept and ranibizumab were approved by the FDA for the treatment of diabetic macular edema in 2015. Bevacizumab is not approved for use in diabetic macular edema. Patients who are treated with any of these agents demonstrate significantly better vision (a gain of three or more lines of vision on the Snellen chart) than individuals treated with laser photocoagulation. Aflibercept may offer a slight advantage in more advanced cases of diabetic macular edema.53

Intravitreal administration of corticosteroids, either by injection or implant, is another treatment option. A Cochrane review found that this therapy had a beneficial effect in stopping the progression of diabetic macular edema, but led to greater risk of increased intraocular pressure and cataract formation.55

Age-Related Cataracts

DIAGNOSIS

Cataracts can be readily detected with a handheld ophthalmoscope. The red reflex appears dull, extinct, or shady in a patient with cataracts (Figure 7). Treatment is not needed for cataracts that do not cause significant visual impairment. Impaired vision, glare sensitivity, or difficulty with nighttime vision (especially when driving) warrants referral to an ophthalmologist.
to counsel older patients to reduce their exposure to ultraviolet light when feasible and to stop smoking. Smoking is also linked to an increased risk of vision loss associated with age-related macular degeneration. Supplements such as those used in the AREDS do not prevent or slow the progression of cataracts.

**Data Sources:** Searches were performed in Pub Med, Healthy People 2020 Structured Evidence Queries (Vision), Essential Evidence Plus, National Guideline Clearinghouse, U.S. Preventive Services Task Force recommendations, Cochrane Database of Systematic Reviews, and the website of the National Eye Institute of the National Institutes of Health. Search terms included eye disease, eye disease in older adults, vision loss, low vision, blindness, and disease-specific terms, including age-related macular degeneration, diabetic eye disease, diabetic retinopathy, glaucoma, ocular hypertension, and age-related cataracts. Search dates: October 2015, December 2015, and May 2016.

Figures 2, 3, 5, 6, and 7 courtesy of Mike Stanley, Department of Ophthalmology, Augusta University.

This review updates a previous article on this topic by Pelletier, et al.1

**The Authors**

ALLEN L. PELLETIER, MD, is a professor in the Department of Family Medicine at the Medical College of Georgia at Augusta University.

LEYD ROJAS-ROLDOAN, MD, is an assistant professor in the Department of Family Medicine at the Medical College of Georgia at Augusta University.

JANIS COFFIN, DO, is an associate professor in the Department of Family Medicine at the Medical College of Georgia at Augusta University.

Address correspondence to Allen L. Pelletier, MD, Medical College of Georgia, HB 4020, Augusta, GA 30912 (e-mail: apelletier@augusta.edu). Reprints are not available from the authors.

**REFERENCES**

Vision Loss in Older Adults


40. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;52(suppl 1):S57-S68.


